SCHEMBL517371

SCHEMBL517371

O=C(O)N1CCN(C2CCNCC2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 6/20 0.45
L3MBTL3 Q96JM7 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
KDM4E B2RXH2 5/20 0.41
ALDH1A1 P00352 3/20 0.41
GABRP O00591 1/20 0.40
GABRD O14764 1/20 0.40
GABRA1 P14867 1/20 0.40
TSHR P16473 1/20 0.40
GABRB1 P18505 1/20 0.40
GABRG2 P18507 1/20 0.40
GABRB3 P28472 1/20 0.40
GABRA5 P31644 1/20 0.40
GABRA3 P34903 1/20 0.40
GABRA2 P47869 1/20 0.40
GABRB2 P47870 1/20 0.40
GABRA4 P48169 1/20 0.40
GABRE P78334 1/20 0.40
PMP22 Q01453 1/20 0.40
GABRA6 Q16445 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3157280 0.89 HTR6 (0.44) HRH3L3MBTL3L3MBTL1KDM4EALDH1A1
SCHEMBL26101903 0.89 HTR6 (0.44) HRH3L3MBTL3L3MBTL1KDM4EALDH1A1
SCHEMBL65329 0.85 HRH3 (0.47) HRH3L3MBTL3L3MBTL1KDM4EALDH1A1
SCHEMBL639911 0.84 L3MBTL3 (0.46) HRH3L3MBTL3L3MBTL1CHRNB2CHRNA3
SCHEMBL29976531 0.84 ITGB3 (0.42) HRH3L3MBTL3L3MBTL1GABRDGABRA1
SCHEMBL3278803 0.82 HRH3 (0.44) HRH3L3MBTL3L3MBTL1KDM4EALDH1A1
SCHEMBL3768409 0.81 POLB (0.56) HRH3L3MBTL3L3MBTL1KDM4EALDH1A1
SCHEMBL65252 0.81 POLB (0.52) HRH3L3MBTL3L3MBTL1KDM4EALDH1A1
SCHEMBL2553841 0.81 HRH3 (0.44) HRH3L3MBTL3L3MBTL1KDM4EALDH1A1
Hydrochloric Acid SCHEMBL28911827 0.81 HRH3 (0.43) HRH3L3MBTL3L3MBTL1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024072178-A1 COMPOUND FOR TARGETED PROTEIN DEGRADATION, AND USE THEREOF (주)사이러스테라퓨틱스 2024-04-04 WO disclosed
US-20230348427-A1 COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF UBIX THERAPEUTICS, INC. (KR) 2023-11-02 US disclosed
CN-116323562-A Compounds with kinase inhibitory activity 上海赛岚生物科技有限公司 2023-06-23 CN disclosed
WO-2022228547-A1 PHOSPHONYL DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF 四川海思科制药有限公司 2022-11-03 WO disclosed
WO-2022194269-A1 NOVEL EGFR DEGRADATION AGENT 上海齐鲁制药研究中心有限公司 2022-09-22 WO disclosed
CN-104302639-B Piperazine-piperidine compounds as hepatitis C virus inhibitors 施万生物制药研发IP有限责任公司 2017-03-29 CN disclosed
EP-2850075-B1 PIPERAZINE-PIPERIDINE COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS THERAVANCE BIOPHARMA R&D IP LLC (US) 2017-02-22 EP disclosed
EP-3057964-A1 SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS Eisai R&D Management Co., Ltd. (JP) 2016-08-24 EP disclosed
US-9206159-B2 Piperazine-piperidine compounds as hepatitis C virus inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (US) 2015-12-08 US disclosed
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
US-7538111-B2 Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain LABORATOIRES FOURNIER S.A. (FR) 2009-05-26 US disclosed
CN-101365693-A Selected CGRP antagonists, method for the production thereof and use thereof as medicaments BOEHRINGER INGELHEIM INT (DE) 2009-02-11 CN disclosed
US-20090018117-A1 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2009-01-15 US disclosed
CN-101255170-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-09-03 CN disclosed
EP-1960368-A1 2,4,5-TRIPHENYL IMIDAZOLINE DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN P53 AND MDM2 PROTEINS FOR USE AS ANTICANCER AGENTS F. Hoffmann-la Roche AG (CH) 2008-08-27 EP disclosed
CN-101172981-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-05-07 CN disclosed
CN-100366624-C 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds OTSUKA PHARMA CO LTD (JP) 2008-02-06 CN disclosed
WO-2007063013-A1 2,4,5-TRIPHENYL IMIDAZOLINE DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN P53 AND MDM2 PROTEINS FOR USE AS ANTICANCER AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2007-06-07 WO disclosed
US-20060178360-A1 Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain LABORATOIRES FOURNIER S.A. (FR) 2006-08-10 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060178360-A1 Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain LTB4R2, BDKRB2, TBXA2R HRH3 863/4885L3MBTL3 4412/4885L3MBTL1 4617/4885
US-20230348427-A1 COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF AR, NR5A1, SHBG HRH3 2865/4885L3MBTL3 4831/4885L3MBTL1 4823/4885
US-20090018117-A1 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF PKD2, QPCT, CCNT2 HRH3 601/4885L3MBTL3 4199/4885L3MBTL1 4181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.